Compare Recursion Pharmaceuticals Inc (RXRX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Tencent Music Entertainment Group - ADR trades at $7.94 (market cap $13.50B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 7.3× Recursion Pharmaceuticals Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.98% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TME | |
|---|---|---|
Market Cap | $1.86B | $13.50B |
Sector | Health | Media |
52-Week High | $6.79 | $26.36 |
52-Week Low | $2.84 | $7.89 |
Enterprise Value | $1.38B | $11.44B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with a bearish technical signal from moving averages but oversold RSI levels. The company reported strong Q2 2026 earnings with a beat on EPS and revenue growth of 6% year-over-year, though recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
The outlook is balanced: TME's low P/E of 9.46 and net income margin of 26.28% offer value, but slowing growth and rising debt pose risks. Analysts have a consensus price target of $12.15, suggesting upside, but investors should weigh competitive threats from rivals like ByteDance's Soda Music against the company's fan economy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
